A Phase 1b Dose Escalation Trial of PSK/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 29 Oct 2015
Price : $35 *
At a glance
- Drugs Docetaxel (Primary) ; Polysaccharide K (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 26 Oct 2015 Status changed from suspended to withdrawn prior to enrolment as per ClinicalTrials.gov record.
- 07 Oct 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.